---
title: "Hengrui Pharma Wins First China Approval for Home-Grown Long-Acting Insulin Analog"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294227320.md"
description: "Jiangsu Hengrui Pharmaceuticals received China's first approval for its domestically developed long-acting insulin analog, insulin sudelidec injection, for treating type 2 diabetes. This milestone strengthens Hengrui's position in chronic disease treatments and biopharmaceutical innovation. Despite the positive regulatory news, technical sentiment signals a 'Strong Sell' for the stock (HK:1276), which has a market cap of HK$408.5B."
datetime: "2026-07-29T14:38:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294227320.md)
  - [en](https://longbridge.com/en/news/294227320.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294227320.md)
---

# Hengrui Pharma Wins First China Approval for Home-Grown Long-Acting Insulin Analog

An update from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) is now available.

Jiangsu Hengrui Pharmaceuticals has obtained approval from China’s National Medical Products Administration to market insulin sudelidec injection, a Class 1 therapeutic biological product it independently developed. The drug is China’s first domestically developed long-acting insulin analog and is indicated for the treatment of adults with type 2 diabetes mellitus.

The approval strengthens Hengrui’s position in high-value chronic disease treatments and the domestic biologics segment, potentially enhancing its competitive edge against multinational insulin producers. It also marks a milestone for China’s biopharmaceutical innovation drive, with implications for patients’ access to advanced diabetes therapies and for the company’s future growth prospects in metabolic diseases.

The most recent analyst rating on (HK:1276) stock is a Buy  
with a HK$92.00 price target.  
To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock,  
see the HK:1276 Stock Forecast page.

**More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H**

Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a leading Chinese drug developer listed in Shanghai and Hong Kong, focused on innovative therapeutics and biologic medicines. The company operates in the pharmaceutical industry with a growing portfolio of Class 1 therapeutic biological products aimed at major chronic diseases such as diabetes.

**Average Trading Volume:** 4,233,238

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** HK$408.5B

### Related Stocks

- [01276.HK](https://longbridge.com/en/quote/01276.HK.md)
- [600276.CN](https://longbridge.com/en/quote/600276.CN.md)

## Related News & Research

- [Hengrui Wins NMPA Nod to Move Cervical Cancer Combo to First-Line Use](https://longbridge.com/en/news/293620453.md)
- [Hengrui Pharma wins China approval for camrelizumab-famitinib combo as 1L cervical cancer treatment](https://longbridge.com/en/news/293617770.md)
- [First China-Made Rapid-Acting Insulin Wins US FDA Approval](https://longbridge.com/en/news/294049451.md)
- [Sunshine Lake Pharma Ships First Interchangeable Insulin Glargine to U.S.](https://longbridge.com/en/news/294499836.md)
- [Guangdong HEC Pharma wins China NMPA approval for insulin degludec injection](https://longbridge.com/en/news/294360356.md)